Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda reports positive Crohn’s disease data for Entyvio

Takeda reports positive Crohn’s disease data for Entyvio

15th December 2016

Takeda has announced the findings of new clinical data analysis that provides evidence of the benefits Entyvio can offer in the treatment of Crohn's disease.

The analysis was based on prespecified and post-hoc exploratory outcomes of the GEMINI II and GEMINI III trials, which evaluated Entyvio therapy in patients with moderate to severely active Crohn's disease.

It was shown that higher rates of response were seen in patients receiving Entyvio as a first-line biologic after conventional therapy failure, compared to patients who had previously failed treatment with an anti-TNF.

Among patients who responded to induction with Takeda's drug at week six, 48.9 percent of TNF-naive and 27.7 percent of TNF-failure patients were in remission at week 52.

Dr Sharon O'Byrne, vice-president and global medical head for Takeda's gastrointestinal specialty area, said: "Crohn's disease is a chronic inflammatory condition resulting in significant impairment of quality of life and requires long-term management with an effective, safe therapy."

Entyvio is a humanised monoclonal antibody that is also designed for use in the treatment of ulcerative colitis.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801829992-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.